Bruce J. Roth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bruce J. Roth has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
David Graham
Carle Clinic
1 shared publication- David J. Vaughn
Abramson Cancer Center, Philadelphia, PA
1 shared publication - Eileen White
Rutgers Cancer Institute, Rutgers University, New Brunswick, USA
1 shared publication George Wilding
University of Wisconsin
1 shared publication- George Wilding
University of Wisconsin Carbone Cancer Center, Madison, WI
1 shared publication Judith Manola
Dana-Farber Cancer Institute
1 shared publication
Latest Publications
- Open Access
- 24 February 2010
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 8 (1) , 20
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC).
- 24 February 2010
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 8 (1) , 20
Open AccessA randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899
To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid (CRA)/interferon-alpha2b (IFN) with paclitaxel (TAX), or mitoxantrone, estramustine and vinorelbine (MEV) will have clinical activity in men with metastatic castrate-resistant prostate cancer (CRPC).
- 1 November 2002
- Published by Springer Nature in Investigational New Drugs
- Vol. 20 (4) , 425-429
Piritrexim in Advanced, Refractory Carcinoma of the Urothelium (E3896): A Phase II Trial of the Eastern Cooperative Oncology Group
This was a single-agent phase II clinicaltrial of the antifol piritrexim in patientswith advanced transitional cell carcinomaof the bladder. Methods: Patientswith previously-treated,...
- 1 November 2002
- Published by Springer Nature in Investigational New Drugs
- Vol. 20 (4) , 425-429
Piritrexim in Advanced, Refractory Carcinoma of the Urothelium (E3896): A Phase II Trial of the Eastern Cooperative Oncology Group
This was a single-agent phase II clinicaltrial of the antifol piritrexim in patientswith advanced transitional cell carcinomaof the bladder. Methods: Patientswith previously-treated,...